The Menkes Disease (Kinky Hair Disease) drugs in development market research report provides comprehensive information on the therapeutics under development for Menkes Disease (Kinky Hair Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Menkes Disease (Kinky Hair Disease). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Menkes Disease (Kinky Hair Disease) and features dormant and discontinued products.
GlobalData tracks five drugs in development for Menkes Disease (Kinky Hair Disease) by five companies/universities/institutes. The top development phase for Menkes Disease (Kinky Hair Disease) is preclinical with four drugs in that stage. The Menkes Disease (Kinky Hair Disease) pipeline has four drugs in development by companies and one by universities/ institutes. Some of the companies in the Menkes Disease (Kinky Hair Disease) pipeline products market are: University of Lorraine, Cyprium Therapeutics and Sentynl Therapeutics.
The key targets in the Menkes Disease (Kinky Hair Disease) pipeline products market include Copper, and Copper Transporting ATPase 1.
The key mechanisms of action in the Menkes Disease (Kinky Hair Disease) pipeline product include Copper Replacement with two drugs in Phase III. The Menkes Disease (Kinky Hair Disease) pipeline products include three routes of administration with the top ROA being Subcutaneous and two key molecule types in the Menkes Disease (Kinky Hair Disease) pipeline products market including Small Molecule, and Gene Therapy.
Menkes Disease (Kinky Hair Disease) overview
Menkes disease, or kinky hair disease, is a progressive disorder that affects copper metabolism in the body. It is caused by mutations in the ATP7A gene, which regulates copper transport. Symptoms include coarse, kinky hair, failure to grow and thrive, neurological degeneration, and nervous system deterioration. It can be diagnosed by low levels of serum copper and ceruloplasmin. There is no cure for Menkes disease, but treatment with parenteral copper histidinate (CuHis) can increase survival.
For a complete picture of Menkes Disease (Kinky Hair Disease)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
